caa a22 4500 465785085 CHVBK 20180323112006.0 cr unu---uuuuu 170327e19900601xx s 000 0 eng 10.1007/BF01268027 doi (NATIONALLICENCE)springer-10.1007/BF01268027 Verbruggen Alfons Laboratory of Radiopharmaceutical Chemistry I.F.W., University Hospital Gasthuisberg, K.U. Leuven, B-3000, Leuven, Belgium aut Radiopharmaceuticals: state of the art [Elektronische Daten] [Alfons Verbruggen] In the past four years most of the effort in radiopharmaceutical chemistry has been devoted to compounds for positron emission tomography, but widespread use of this technique is still compromised by its high cost. On the other hand, steady progress has also been made in the development of technetium-99m-labelled radiopharmaceuticals. A variety of99mTc-labelled agents is now available or in clinical evaluation for the study of brain perfusion (99mTc-labelled HMPAO, ECD, MRP20), myocardial perfusion (99mTc-labelled MIBI, teboroxime and phosphines) and renal function (99mTc-MAG3,99mTc-L,L-EC). Different direct reduction methods and indirect conjugation methods have been developed to label antibodies or their fragments efficiently with99mTc with preservation of immunoreactivity. However, the strict requirements of the regulatory authorities with respect to purification and quality of these preparations limit their use drastically in clinical practice. Radiopharmaceuticals labelled with beta-emitting radionuclides for radioimmunotherapy and palliative treatment of skeletal metastases are receiving increasing interest. Numerous agents are now available for imaging inflammation, but more clinical experience is required to determine which of them is the most appropriate. The growing importance of radiolabelled receptor-imaging agents is apparent from the commercial availability of the first such compound in Europe. Springer-Verlag, 1990 Positron emission tomography nationallicence Technetium 99m-labelled perfusion agents nationallicence Renal function agents nationallicence Radiolabelled antibodies nationallicence Radioimmunotherapy nationallicence Receptor imaging agents nationallicence European Journal of Nuclear Medicine Springer-Verlag 17/6-8(1990-06-01), 346-364 0340-6997 17:6-8<346 1990 17 259 https://doi.org/10.1007/BF01268027 text/html Onlinezugriff via DOI 1 review-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/BF01268027 text/html Onlinezugriff via DOI NATIONALLICENCE 100 1- Verbruggen Alfons Laboratory of Radiopharmaceutical Chemistry I.F.W., University Hospital Gasthuisberg, K.U. Leuven, B-3000, Leuven, Belgium aut NATIONALLICENCE 773 0- European Journal of Nuclear Medicine Springer-Verlag 17/6-8(1990-06-01), 346-364 0340-6997 17:6-8<346 1990 17 259 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer